TH1ADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF This application claims priority to U.S. provisional patent application no. 60/812,146, filed on June 9, 2006, which is hereby incorporated by reference in its entirety. Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein. This patent disclosure contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure, as it appears in the U.S. Patent and Trademark Office patent file or records, but otherwise reserves any and all copyright rights whatsoever. 1. FIELD OF THE INVENTION The present invention relates to Thiadiazole Compounds, as defined bdow; compositions comprising an effective dose of a Thiadiazole Compound; and methods for treating or preventing a metaUoproteinase-related disorder comprising administering to a mammal in need thereof mi effective dose of a Thiadiazole Compound. 2. BACKGROUND OF THE INVENTION Metalloproteinases, including matrix metal ioproteinases and aggrecanases, are known to have a role in the breakdown of connective tissue. Matrix metalloproteinases ("MMPs") constitute a superfamily of proteolytic enzymes that are genetically related and capable of degrading almost all the constituents of extracellular matrix and basement membrane that restrict cell movement. Aggrecanases are members of the ADAMTS (A disintegrin and metal loproteinase with thrombospondin motifs) family of proteins. Aggrecanase-1 and aggrecanase-2 have been designated ADAMTS-4 and ADAMTS-5, respectively (Tang, Int. J. Biochem. Cell. Biol. 33:33-44 (2001)). The ADAMTS family is involved in cleaving aggrecan, a cartilage component also known as the large aggregating chondroitin sulphate proteoglycan (Abbaszade et ai.,J Biol. Chem. 274:23443-23450 (1999)), procollagen processing (Colige et al., Proc. Natl. Acad. Sci. USA 94:2374-2379 (1997)), angiogenesis and tumor invasion (Vazquez et al., J. Biol. Chem, 274:23349-23357 (1999)), inflammation (Kuno et al., J. Biol. Chem. 272:556-562 (1997)). MMPs have been shown to cleave aggrecan as well. The loss of aggrecan has been implicated in the degradation of articular cartilage in arthritic diseases, for example osteoarthritis is a debilitating disease which affects at least 30 million Americans. Degradation of articular cartilage and the resulting chronic pain can severely reduce quality of life. An early and important characteristic of the osteoarthritic process is loss of aggrecan from the extracellular matrix, resulting in deficiencies in the biomechanical characteristics of the cartilage. Likewise, MMPs and aggrecanases are known to play a role in many disorders in which extracellular protein degradation or destruction occurs, such as cancer, asthma, chronic obstructive pulmonary disease ("COPD"), atherosclerosis, age-related macular degeneration, myocardial infarction, corneal ulceration and other ocular surface diseases, hepatitis, aortic aneurysms, tendonitis, central nervous system diseases, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, inflammatory bowel disease, shock, invcrtebral disc degeneration, stroke, osteopenia, and periodontal diseases. Accordingly, there is a need for metalloprotetnase inhibitors, such as inhibitors of MMPs and aggrecanases. The present invention addresses this need. 3. SUMMARY OF THE INVENTION The present invention relates to Thiadiazoie Compounds; compositions comprising an effective dose of a Thiadiazoie Compound; and methods for treating or preventing a metalloproteinase-related disorder, such as, an arthritic disorder, osteoarthritis, cancer, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia or a periodontal disease comprising administering an effective dose of a 'Ihiadiazole Compound to a mammal in need thereof. In one embodiment, the invention provides compounds of the Formula (I): (Formula Removed) or a pharmaceutically acceptable salt or hydrate thereof, wherein X is -iCH2)m-C(O)O-, -CCH2)m-C(O)NH- or-(CH2)m-SO2-; m is 0 or 1; each Y is -CCR3)-; R1 is -aryl or -5 or 6-membered aromatic or non-aromatic heterocycle, wherein the -aryl or -S or 6-membered aromatic or non-aromatic heterocycle group is unsubstituted or substituted with one or more R4 groups; R2 is -H, -C1-C6 alkyl, -C2-C5 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyi)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein the -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 aikyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 aikyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstituted or substituted with one or more of the following groups: -halo, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, -O-C2-C6 alkynyl, -O-aryl, -0-(C1-C6 alkyl)-aryl, -0(5 or 6-membered aromatic or non-aromatic heterocycle), -CHC1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -N02, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH (C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)0-(C,-C« alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2; each R3 is independently -H, -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic hcterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycIe>-C1-C6 alkyl, -NH2> -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2; and each R4 is independently -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C1-C6 alkyl, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or-C(O)N(C1-C6 alkyl)2. In one embodiment, the invention provides compounds of the Formula (II): (Formula Removed) or a pharmaceutically acceptable salt or hydrate thereof, wherein X1 is -CH2-, -(CH2)m-C(O)-, -(CH2)m-C(O)NR2-, -(CH2)m-C(O)O-, -(CH2)m-C(O)NH- or -(CH)-SO2-; m is 0 or 1; n is 0 or 1; each Y1 is independently -C(R3)- or -N-, wherein at least one occurrence of Y is -N-; R1 is -aryl or -5 or 6-membered aromatic or non-aromatic heterocycle, wherein the -aryl or -5 or 6-membered aromatic or non-aromatic heterocycle group is unsubstituted or substituted with one or more R4 groups; R2 is -H, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, (C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein the -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -{C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstituted or substituted wim one or more of the following groups: -halo, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, -O-C2-C6 alkynyl, -O-aryl, -O-(C1-C6 alkyl)-aryl, -0(5 or 6-membered aromatic or non-aromatic heterocycle), -O-(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -CN, - alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCT}, -NO2, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)*, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(CI-C6 alkyl), -SO2N(C1-C6 alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2; each R3 is independently -H, -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C1--C6 alkynyl, -CF3, -OCF3, -NO2, -(C1-C6 alkylH5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C1-C6 alkyl, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)z, -NHC(O)-(C1-C6 alkyl), -NHCCOPHC12-C6 alkyl), -SOaNHa, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkylfc, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C,-C6 alkyl)2; and each R4 is independently -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, (5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocyclic alkyl, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NHz, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyll)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(d-C6 alkyl)2. In one embodiment, the invention provides compounds of the Formula (III)" (Formula Removed) or a pharmaceutically acceptable salt or hydrate thereof, wherein X1 is -CH2-, -(CH2)m-C(O)-, -(CH2)m-C(O)NR2-, -(CH2)m-C(O)O-(CH2)m-C(O)NH- or -{CH)m-SO2-; m is 0 or 1; n is 0 or I; each Y is independently -C(R3)- or -N-; R9 is -5 or 6-membered aromatic or non-aromatic heterocycle, which is unsubstitutcd or substituted with one or more R4 groups; R2 is -H, -C1-C6 alkyl, -C2-C6 alkenyi, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein the -C1-C6 alkyl, -C2-C6 alkenyi, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic, or non-aromatic heterocycle or -{C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstituted or substituted with one or more of the following groups: -halo, -O-C1-C6 alkyl, -O-C2-C6 alkenyi, -O-C2-C6 alkynyl, -O-aryl. -O-(C1-C6 alkyl)-aryl, -O-(5 or 6-membered aromatic or non-aromatic heterocycle), -O-(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -CN, -C1-C6 alkyl, -C2-C6 alkenyi, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyll)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2; each R3 is independently -H, -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyi, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -(5 or 6- membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C1-C6 alkyl, -NH2, -NH(C1-C6 alkyl), -N(C(-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SCbNCC1-C6 alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2; and each R4 is independently -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocyclc), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C1-C6 alkyl, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkylh, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2- In one embodiment, the invention provides compounds of the Formula (IV): (Formula Removed) or a pharmaceutically acceptable salt or hydrate thereof, wherein X2 is -CH2-, -(CH2)m-C(O)O-, -(CH2)m-C(O)NH-, -(CH2)m-C(O)NR2-, or -(CH)m- SO2 each Y is independently -C(R3)- or -N-; m is 0 or 1; n is 0 or 1; R2 is -H, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 o; 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein the -C1-C6 alkyl, -C2-C6 alkenyl, -C1-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic 01 non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstiruted or substituted with one or more of the following groups: -halo, -O-C1-C6 alky], -O-C2-C6 alkenyl, -O-C2-C6 alkynyl, -O-aryl, -O-(C1-C6 alkyl)-aryl, -O-(5 or 6-membered aromatic or non-aromatic heterocycle), -O-(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -CN, -C1-C6 alkyl, -C2-C6 alkenyl, ~C2-C6 alkynyl, -CF3, -OCF3, -NO2, -NHj, -NH(C1-C6 alkyl), -N(C1-C6 alkylh, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6, alkyl), -SO2N(C1-C6 alkylh, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or-C(O)N(C1-C6 alkyl)2; and each R3 is independently -H, -halo, -OR2, -CN, -C1-C* alkyl, -C2-C« alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-merabcred aromatic or non-aromatic heterocycle)-aryl, -(5 or 6-membered aromatic or non-aromatic hetcrocycle)-CH2-aryl, -(5 or 6-membcred aromatic or non-aromatic heteracyclc)-C1-C6 alkyl, -NH2, -NHC1-C6 alkyl), -N(C1-C6 atkyifc, -NHC(O)-(C1-C6 aflcyi), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SOjNC1-C6alkyl), -SO2N(C1-C6 alkyl),, -NHSCb(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(p)N(C,- C«alkyl)2. wherein th« -OCH3 depicted in Formula (IV) occupies the para position or an ortho or meta position on the phenyl ring to which it is attached. In one embodiment, the invention provides compounds of the Formula (V): (Formula Removed) or a phannaceutically acceptable salt or hydrate thereof, wherein X3 is -CH2-, -(CH2)m-C(O)O-, -(CH2)m-C(O)NH-, or -(CH2)m-SO2-; each Y is independently -C(R8)- or -N-; misOor 1; n is 0 or 1; each R6 is independently -H, -C1-C6 alkyl, or -halo; R7 is -H, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(Ct-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein a -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstittited or substituted with one or more of the following groups: -halo, -O-C|-C« alkyl, -O-C1-C6 alkenyl, -O-C2-C6 alkynyl, -O-aryl, -CHC1-C6; alkyl)-aryl, -O-(5 or 6-membered aromatic or non-aromatic heterocycle), -O-(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -CN, -C1-C6 alkyl, C1-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2. -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkylfc, -NHCCOHC1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2(C1-C6 alkyl), -SO2N(C1-C6 alkyl),, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), such that when n is 0, R7 is not -H; and each R8 is independently -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NCh, -(Ci-Cft alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -{5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -(5 or 6-membered aromatic or non-aromatic heterocyclc)CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C-Qs alkyl, -NH2, -NHC C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkylfc, -NHS(32(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -CCOMC1-C6 alkylja- In one embodiment, the invention provides compounds of the Formula (VI): (Formula Removed) or a pharmaceutically acceptable salt or hydrate thereof, wherein X4 is -CH2-, -C(O)-, -(CH2)m-C(O)O-, -(CH2)ra-C(O)NH, or (CH2)-SO,-; each Y is independently -C(R3)- or -N-; m is 0 or 1; n is 0 or 1; each R9 is independently -H, -C1-C6 alkyl, -O-C1-C6 alkyl, or -halo; R2 is -H, -C1-C6 alkyl, -C1-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein the -C1-C6 alkyl, -C2-C6 alkenyl, -C1--C6, alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstituted or substituted with one or more of the following groups: -halo, -O-C1-C6 alkyl, -OC2-C6 alkenyl, -O-C2-C6 alkynyl, -O-aryl, -O-(C1-C6 alkyl)-aryl, -0(5 or 6-membered aromatic or non-aromatic heterocycle), -O-(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -CN, -C1-C6 alkyl, -C2-C6 alkenyl,-C2-C6 alkynyl, -CF3, -OCF3, -NOz, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2> -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-Q alkyl), -SO2N(C1-C6 alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2; and each R3 is independently -H, -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -Q-Q alkynyl, -CFj, -OCF3, -NO2, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C1-C6 alkyl, -NH2> -NH(C1-C6 alkyl), -N(C1-C6 alkyDz, -NHC(O) (C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SQzNHj, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)*, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C:(O)NH(C1-C6 alkyl), or -C(O)N(C-C6 alkyl)2, such that: every R9and every R3 are not simultaneously -H when n is 0 and R2 is -H, methyl, ethyl, butyl, pentyl, or an unsubstituted or mono- or di-substituted -(C1-C6 alkyl)-aryl; R9 and R2 are not simultaneously -H when n is 0, exactly one R3 group is bromo, isopropyl, ethyl, or methyl and the other R3 groups are -H; R2 is not naphthyl, methyl, butyl, or pentyl when every R9 and R3 group is —H and n is 0; R2 is not -H or methyl when n is 0, exactly one R* group is methyl while the other R9 groups are -H, and every RJ group is -H or exactly one R3 group is methyl or ethyl while the other RJ groups are —H; R3 is not naphthyl substituted with exactly one -halo or one -NO2 group, or phenyl substituted with exactly one -halo or one -NO2 group, when (X)n is -CH2- and every R9 and R3 group is —H or exactly one R9 group is methyl and the other R9 and R3 groups are -H; R2 is not —H, methyl, or -(C1-C6 alkyI)-(5 or 6-membered non-aromatic heterocycte) when exactly one R* group is methyl, n is 0, and every R3 group is -H; X4 is not -C(O)- and R2 is not propyl or methyl when every R3 is -H, n is 1, and every R9 is -H or exactly one R9 is -O-(C1-Q alkyl) and the other R9 groups are -H; exactly OIK R3 group is not methyl, ethyl, or isopropyl when the other three R3 groups are -H, and each R9 group is —H or the R9 group at the para position is methyl and the othcr R9 groups are -H, and R2 is -H; and the R3 groups do not comprise exactly one methyl and exactly one -halo or the R3 groups do not comprise exactly two methyl groups at the 6 and 7 positions of the indoline ring when n is 0 and R2 and every R9 are -H. In one embodiment, the invention provides compounds of the Formula (Vli): (Formula Removed) or a pharmaceutically acceptable salt or hydrate thereof, wherein X4 is -CHa-, -C(O)-, -(CH2)ro-C(O)O-, -(CH2)m-C(O)NH, ~(CH2)m-C(O)NR2, or (CH2)ra-SO2-; each Y is independently -C(R3)- or -N-; m is 0 or 1; n is 0 or 1; each R9 is independently-H, -C1-C6 alkyl, -O-C1-C6 alkyl, or halo; R2 is -H, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein the -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -{C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstituted or substituted with one or more of the following groups: -halo, -O-Ci-C* alkyl, -O-C1-C6 alkenyl, -O-C1-C6 alkynyl, -O-aryl, -CH C1-C6 alkyl)-aryl, -O-(5 or 6-membered aromatic or non-aromatic heterocycle), -O-(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CFj, -OCF3, -NOz, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkylh, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SOjNHCC1-C6 alkyl), -SO2N(C1-C6 alkyl)2, -NHSCMC-Ce alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2; and each R3 is independently -H, -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -{C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryI, -(5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C1-C6 alkyl, -NH2) -NH(C1-C6 alkyl), -N(C1-C6alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH-toluenesulfonate, and pamoate (i.e., 1,l'-methylene-bts-(2-hydroxy-3-naphthoate)) salts. The pharmaceutically acceptable salt can also be a camphorsulfonate salt. The term "pharmaceutically acceptable salt" also refers to a salt of a Thiadiazole Compound having an acidic functional group, such as a carboxylic acid functional group, and a base. Suitable bases include, but are not limited to, hydroxides of alkali metals such as sodium, potassium, and lithium; hydroxides of alkaline earth metals such as calcium and magnesium; hydroxides of other metals, such as aluminum and zinc; ammonia, and organic amines, such as unsubstituted or hydroxy-substituted mono-, di-, or tri-alkylamines, dicyclohexylamine; tributyl amine; pyridine; N-methyl, N-ethylamine, diethylamide; triethylamine; mono-, bis-, or tns-(2-OH-lower alkylamines), such as mono-; bis-, or tris-(2-hydroxyethyl)amine) 2-hydroxy-ferr-butylamine, or tris-(hydroxymethyl)methylamine, N,N-di-lower alkyl-N-(hydroxyl-lower alkyl)-amines, such as N,N-dimethyl-N-(2-hydroxyethyl)amine or tri-(2-hydroxyethyl)amine; N-methyl-O-glucaraine; and amino acids such as arginine, lysine, and the like. The term "pharmaceutically acceptable salt" may also include a pharmaceutically acceptable salt of a hydrate of a Thiadiazole Compound. A "mammal" is a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus. In one embodiment, a mammal is a human. The following abbreviations are used herein and have the indicated definitions: ACN is acetonitrile; CHO is Chinese hamster ovary; DMSO is dimethylsulfoxide; EtOH is ethanol; Et20 is diethyl ether; HEPES is N (2 hydroxyethyl) piperazine-N'-(2 ethanesulfonic acid); HPLC is high-performance liquid chromatography; LC/MS is liquid chromatography/mass spectrometry; and RFU is relative fluorescence units. A3. THE THIADIAZOLE COMPOUNDS 4.2.1 THE THIADIAZOLE COMPOUNDS OF FORMULA (I) As stated above, the present invention encompasses Thiadiazole Compounds having the Formula (I): (Formula Removed) or a pharmaceutically acceptable salt or hydrate thereof, wherein X, Y, R1 and R2 are as defined above for the Thiadiazole Compounds of Formula (I). In one embodiment, each occurrence of Y is -CH-. In one embodiment, three occurrences of Y are -CH-. In one embodiment, tiiree occurrences of Y are -CH- and one occurrence of Y is -C(R3)-. In one embodiment, X is -(CH2)m-C(O)O-. In another embodiment, X is -{CH2)m-C(O)NH-. In still another embodiment, X is —(CH2)m-SO2- In one embodiment, R1 is aryl. In one embodiment, R1 is phenyl. In one embodiment, R1 is phenyl, substituted with one or more -O-(C1-C6 alkyl) groups. In another embodiment, R1 is 2-methoxyphenyl. In still another embodiment, R1 is 3-methoxyphenyl. In yet another embodiment, R1 is 4-methoxyphenyl. In one embodiment, R1 is phenyl, substituted with one or more -C1-C6 alkyl In one embodiment, R1 is phenyl, substituted with one or more methyl groups. In one embodiment, R1 is phenyl, substituted with one isopropyl group. In another embodiment, R1 is 3-methylphenyl. In another embodiment, R1 is 4-methylphenyl. In another embodiment, R1 is 4-isopropylphenyl. In one embodiment, R1 is phenyl, substituted with one or more halo groups. In one embodiment, R1 is phenyl, substituted with one fluoro group. In one embodiment, R1 is phenyl, substituted with one chloro group. In one embodiment, R1 is 4-fluorophenyl. In another specific embodiment, R1 is naphthyl. In one embodiment, R2 is -H. In another embodiment, R2 is -Ci-Q alkyl. In a specific embodiment, R2 is methyl. In another specific embodiment, R2 is ethyl. In one embodiment, R2 is -(Ci-Cs alkyl)-N(C!-C6 alkyl )2 In a specific embodiment, R2 is -(CH2)2N(CH3)2. In one embodiment, R2 is H;CH2)mC(O)O-(C1-C6 alkyl). In another embodiment, R2 is -C2-C6 alkenyl. In another embodiment, R2 is -C2-C6 alkynyl. In a specific embodiment, R2 is -CH2-C=CH. In another embodiment, R2 is -aryl In a specific embodiment, R2 is —phenyl. In another embodiment, R2 is -(C1-C6 alkyl)-aryl. In a specific embodiment, R2 is -benzyl. In another embodiment, R2 is -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle). In another embodiment, R2 is -5 or 6-membered aromatic or non-aromatic heterocycle. In one embodiment, at least one occurrence of R3 is -halo. In a specific embodiment, at least one occurrence ofR3is-Cl. In another specific embodiment, at least one occurrence of R is —Br. In another specific embodiment, at least one occurrence of R3 is —F. In one embodiment, at least one occurrence of R3 is -O-(C1-C6 alkyl). In a specific embodiment, at least one occurrence of R3 is —OCH3. In one embodiment, at least one occurrence of R3 is -C1-C6 alkyl. In a specific embodiment, at least one occurrence of R3 is methyl. In another specific embodiment, at least one occurrence of R3 is ethyl. In yet another specific embodiment, at least one occurrence of R3 is n-propyl. In another specific embodiment, at least one occurrence of R3 is isopropyl. In a specific embodiment, at least one occurrence of R3 is -CF3. In another specific embodiment, at least one occurrence of R3 is-OCF3. -: In yet another specific embodiment, at least one occurrence of R3 is-NCh. In one embodiment, at least one occurrence of R3 is -5 or 6-membered aromatic or non-aromatic heterocycle. In a specific embodiment, at least one occurrence of R3 is piperazin-1-yl. In one embodiment, at least one occurrence of R3 is -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle). In one embodiment, at least one occurrence of R3 is -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl. In one embodiment, at least one occurrence of R3 is -(5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl. In one embodiment, two occurrences of R3 are independently C1-C6 alkyl. In a specific embodiment, two occurrences of R are methyl. In one embodiment, one occurrence of R3 is C1-C6 alkyl and another occurrence of R is halo. In another embodiment, one occurrence of R is 5 or 6-membered non-aromatic heterocycle and another occurrence of R3 is halo. In one embodiment, a compound of Formula (I) is in isolated and purified form. 4.2.2 THE THIADIAZOLE COMPOUNDS OF FORMULA (II) As stated above, the present invention encompasses Thiadiazole Compounds having the Formula (II): (Formula Removed) or a pharmaceutically acceptable salt or hydrate thereof, wherein X1, Y1, n, R1 and R2 a~e as defined above for the Thiadiazole Compounds of Formula (II). In one embodiment, three occurrences of Y1 are —C(R3)- and one occumnce of Y1 is --N-. In another embodiment, two occurrences of Y1 are -C(R3)- and two occurrences of Y1 are —N-. In yet another embodiment, one occurrence of Y1 are -C(R3)- and three occurrences of Y are —N-. In one embodiment, each occurrence of Y1 is -N-. In one embodiment, each occurrence of-C(R3)- is -CH-. In one embodiment, X1 is -{CH2)m-C(O)O-. In another embodiment, X1 is -(CH2)m-C(O)NH-. In still another embodiment, X1 is -CH2- In yet another embodiment, X1 is -(CH2)m-C(O)-. In a further embodiment, X1 -{CH2)m-SO2-. In another embodiment, X1 is -2N(CHj)2. In one embodiment, R2 is -2- In one embodiment, n is 1. In another embodiment, n is 0. In one embodiment, m is 1. In another embodiment, m is 0. In one embodiment, each occurrence ofR6is-H. In another embodiment, four occurrences of R6 are -H. In still another embodiment, three occurrences of R6 are -H. In one embodiment, one occurrence of R6 is C1-C6 alkyl. In another embodiment, two occurrence of R are C1-C6 aikyl. In still another embodiment, one occurrence of R6 is methyl. In yet another embodiment, one occurrence of R6 is isopropyl. In one embodiment, R6 is -halo. In another embodiment, one occurrence of R6 is -F. In one embodiment, R is in the para position on the phenyl ring to which i! is attached. In another embodiment, R6 is in an ortho position on the phenyl ring to which it is attached. In still another embodiment, R6 is in a meta position on the phenyl ring to which it is attached. In one embodiment, R is H. In another embodiment, R7 is not H. In yet another embodiment, R7 is -Ci-Ca alkyl. In a specific embodiment, R7 is methyl. In another specific embodiment, R7 is ethyl. In one embodiment, R7 is -one (Compound 2) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and 1-methylindoline-2,3dione as the isatin compound, Compound 2 was prepared. Example 4 Preparation of 5,-(4-methoxyphenyl)-3,J«-$piro(indole-3>2'-[l,3,41thiadiazolJ-2(liO-«ne (Compound 3) Using the method set forth in Example 1 and using 4-methoxybenzodiiohydrazide as the thiobenzoylhydrazine compound and indoline-2,3-dione as the isatin compound, Compound 3 was prepared. Example 5 Preparation of 5-bromo~5'-(4-BiethoxyphenyI>-3,//-spiro|indole-3,2,-ji,3,4)thiadiazolj- 2(l//)-one (Compound 4) Using the method set forth in Example 1 and using 4-methoxybenzodiiohydraztde as the thiobenzoylhydrazine compound and 5-bromoindoline-2,3-dione as the isatin compound, Compound 4 was prepared. Example 6 Preparation of 5'-(4-methoxyphenyi)-5-methyl~31//~spiro[indole-3,2'-[l,3,4Jthiadiazolj- 2{AH}-one (Compound 5) Using the method set forth in Example I and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and 5-rnethylindoline-2,3-dione as tne isatin compound, Compound 5 was prepared. Example 7 Preparation of 5-methoxy-5'-(4-methoxyphenyl)-3,i/-spirolindole-3,2'-[l,3,4]tliiadiaz©lJ- 2(Lff)-one (Compound 6) *»nj. Using the method set forth in Example 1 and using 4-m*thoxybenzothiohydrazide as the thiobenzoylhydrazine compound and 5-methoxyindoline-2,3-dione as the isatin compound, Compound 6 was prepared. Example 8 Preparation of 5'-(4-methoxyphenyI)-l-prop-2-yn-l-yJ-3'//-spiro[indole-3r2'-llr3,4Jthiadiazol]-2(l/f>one (Compound 7) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and l-(prop-2-ynyl)indoline-2,3-dione as the isatin compound, Compound 7 was prepared. Example 9 Preparation of 5'-(4-methoxyphenyl)-l-(3-(trinuoromethyl)phenyl]-3,H-spiro|indole-3^,-fl3,4]thiadiazoI]-2(lH)-one (Compound 8) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and l-(3- trifluorometbylphenyl)indoHne-2,3-dione as the isatin compound, Compound 8 was prepared. Example 10 Preparation of ethyl [S'-^-methoxyphenyO^-oxo-S'H-spiroIindole-S^'-[l,3,4]thiadiazoI|-l(2H)yl]acetatc (Compound 9) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and ethyl-2-<2,3-dioxoindolin-l-yl)acetate as the isatin compound, Compound 9 was prepared Example 11 Preparation of l^beit2yl-5'-(4-methoxyphenyI)-3'H-spiro[ind©Ie-3,2,-{l,3,4]thiadiazoIJ- 2(lH)-one (Compound 10) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and 1-benzylindoline- 2,3-dione as the isatin compound, Compound 10 was prepared. Example 12 Preparation of l-JMd|U^»•thy^amino)ethy^J-5,-(4-methoxyphenyI)-3,H-«plrollndole-3^2,- {13,4ithiadiazoI]-2(lH) one (Compound 11) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and l-(2-(dimethyIamino)e&yi)imloKn-2,3-dione as the isatin compound, Compound 11 was prepared. Example 13 Preparation of 6-chloro-5'-(4-methoxyphenyl)-3,H-spiroJindole-3,2,-[13,4JthiadiaJtoll- 2(lH}-one (Compound 12) Using the method set forth in Example 1 and using 4- mcthoxybenzothiohydrazide as the thiobenzoylhydrazine compound and 6-chloroindohne- 2,3-dione as the isatin compound, Compound 12 was prepared. Example 14 Preparation of S-ehtero-S'^-methoxyphenyl^'H-spirofuidoIe-S^'-ll^^JthiadiazoIJ- 2(lH)-one (Compound 13) (O636) Using the method set forth in Example 1 and using 4- methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and 5-chloroindoline- 2,3-dione as the isatin compound, Compound 13 was prepared. Example 15 Preparation of 4-{4-beIKeylpiperazin-l-yi)-5,-(4-nlethoxyphenyI)-3'H-spiro|indoIe-3,2,- [l,3,41thiadiazoJJ-2(lrT)-one (Compound 14) Using the method set forth in Example 1 and using 4- methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and 4-(4- benzylpiperazin-l-yl)indoline-2,3-dione as the isatin compound, Compound 14 was prepared. Example 16 Preparation of S'-(4-methoxyphenyl)-6-propy]-3'H-spiro|indole-3,2'-[l^,4JthiadiazolJ- 2(lH>-one (Compound IS) Using the method set forth in Example 1 and using 4- methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and 6-propylindoline- 2,3-dione as the isatin compound, Compound IS was prepared. Example 17 Preparation of 5,-<4-«nethoxyphenyl)-5-nitro-3,rl-spiroIindole-3,2,-|lr3,4)thiadiazo))- 2(lH)-one (Compound 16) Using the method set forth in Example 1 and using 4- methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and 5-nitroindoline-2,3- dione as the isatin compound. Compound 16 was prepared. Example 18 Preparation of 6-chIoro-5,-(4-methoxyphenyI)-7-methyt-3'H-spirone (Compound 18) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoyihydrazine compound and 7-methylindoline-2,3-dione as the isatin compound, Compound 18 was prepared. Example 20 Preparation of 5'-<4-nietAoxyphenyl)-6-niethyl-3,H-spiro[indole-3,2,-(13»4JthiadiazolJ- 2(lH)-one (Compound 19) Using the method set forth in Example 1 and using 4- methoxybenzothiohydrazjde as the thiobenzoyihydrazine compound and 6-methylindoline- 2,3-dione as the isatin compound, Compound 19 was prepared. Example 21 Preparation of 7-■letlM»xy-5,-(4-methoxyphenyl)-6-lllethyl-3,H-spu•o^indole-3y2,-(l,3,41thiadiazol]-2(lH)-one (Compound 20) Using the method set forth in Example 1 and using 4- methoxybenzothiohydrazide as the thiobenzoyihydrazine compound and 6-methyl-7- methyoxyindoline-2,3--dione as the isatin compound, Compound 20 was prepared. Example 22 Preparation of l-ethyl-5-fluoro-5,-(4-methoxyphenyl)-6-(4-methylpiperazin-l-yl)-3,H-spiro|indole-3,2'-|l,3,4]thiadiazol]-2(lH)-one (Compound 21) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoyihydrazine compound and ]-ethyl-5-fluoro- 6-(4-methylpiperazin-l-yI)indoline-2,3-dione as the isatin compound, Compound 21 was prepared. Example 23 Preparation of l-benzyI-5'-(4-methoxyplienyl)-5-metliyt-3,H-s}3irt>iimiole-3,2'-{l,3,4]thiadiazol]-2(lH)-one (Compound 22) Using the method set forth tn Example 1 and using 4-methoxybenzothiohydrazide as die thiobenzoylhydrazine compound and I -benzyl-5-methylindoline-2,3-dione as the isatin compound, Compound 22 was prepared. Example 24 Preparation of S'^-mcthoxyphenyO-S-methyl-l^-methylphenyO-S'H-spirolindole-3,2'-|l,3,4Jthiadiazol]-2(lH)-one (Compound 23) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and l-(2- methylphenyl)-5-methylindoIine-2,3-dione as the isatin compound, Compound 23 was prepared. Example 25 Preparation of 5'-(4-methoxyphenyl)-5-methyH-(4-methylphenyl)-3'H-»piro[indole-3^2'-f l^,4IthiadiazolI-2(lH)-one (Compound 24) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and l-(4- methylpheayl)-5-methylindoiine-2,3-dione as the isatin compound, Compound 24 was prepared. Example 26 Preparation of l-(4-cfeiloro|AenyI)-S'-(4-methoxyphenyl)-5-methyI-3'H-spiro[indole-3>2'- |l,3,4]thiadiazol]-2(HJ)-one (Compound 25) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and l-(4- chlorophenyl)-5-methylindoline-2,3-dione as the isatin compound, Compound 25 was prepared. Example 27 Preparation of l-(3,4-dichlorophenyI)-5'-{4-methoxyphenyl)-5-methyl-3'H-spirojindole-3;T-p3,4)thiadiazo!J-2(lH)-one (Compound 26) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and l-{3,4- dichiorophenyl)-5-methyIindoline-2,3-dione as the isatin compound, Compound 26 was prepared. Example 28 Preparation of 5'-{4-methoxyphenyi>S-methyI-l-{3-nitrophenyi)-3,H-spiro|indole-3^!*- fl,3,4Jthiadiazolj-2(lH)-one (Compound 27) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and l-(3-nitropheny!)-5~methyliBdoiine-2,3~dione as the isatin compound, Compound 27 was prepared. Example 29 Preparation of l-^M5B2y^-5*-(4-^iethoxyphenyl)-6-propyl-3'^-spir5c»JMldole-3^•-f l,3*4}titiactiftzol]~2(Lff)-oiie (Compound 28) Usiag the method set forth in Example 1 and using 4-methoxyberoothiohydrazide as the thiobenzoylhydrazine compound and l-benzyl-6- propylindoline-2,3-dio«e as the isatin compound, Compound 28 was prepared. Example 30 Preparation of 5-ethyl-5,-(4-methoxyphenyI)-3,H-spiro|todoIe-3,2,-[ 13,4Jthiadia2©lJ- 2(1 H>oae (Compound 29) Using the method set forth in Example 1 and using 4-methoxybenzothiohydrazide as the thiobenzoylhydrazine compound and 5-ethylmdoline- 2.3-dione as the isatin compound, Compound 29 was prepared. Example 31 Preparation of 5-ethyl-S,-(3-tnethoxyphenyI)-3'H-spirolindolc-3,2'-{ t^3,4}thiadiazol|~ 2(!JH)-one (Compound 30) Using th-e method set fonh ;n Ex,ini\>lc 1 m,d u^ing 3 -methoxybenzortiiohydrazide as ibe thiobenzo>lhydra7.inc compound and 5-ethylitidoiine~ 2,i3-dione as the isatm compound, Compound 3f> w;*s prepared. Example 32 Preparation of S'-pheayl-S^trifluororoetboxy^'H-spirojindole-J^'-lljJ^jthiadiaxolJ- 2(lH)-one (Compound 31} Using the memod set forth in Example 1 and using benzotbiohydiazide as the thiobenzoylhydrazine compound and 5-(trifluromethoxy)isopropylindoIine-2,3-dione as the isatin compound. Compound 31 was prepared. Example 33 Preparation of S-methyJ-l-Cl-mMhylphenyiySM^-methyiphenyl^'B-^piroIindolfc-S,!'- tl,3,4i«iiadiaK©ll-2-oiie (Compound 33) Dsiag the method set forth in Example I end using 4-memyfcenzothiohydrazide as the thiobenzoylbydrazine coTnpoxmd and V~(2-m«thylphessy!>- 5-methyKndoJme-23-dione as the isatin compound, Compound 32 was prepared. Example 34 Preparation of l-b««KEyl-5-B»ethyl-S,-{4-methyJph^K^y^>-3fH-spiro{i»d©l€s3^2,-f I A+JtM»diazoi}-2{lH)-on* (Compound 33) Using the method set forth in Example i and using 4-methylbenzothiohydrazide as the thiobenzoylhydrazine compound and l-benzyl-5-«iethylindoline-2,3-dione as die isatin compound, Compound 33 was prepared. Example 35 Preparation of 5,7-di«iethyI-S'-plieriyl-3'//-spiro{indole-3,2'-{l,3,4jrhiadiazoij-2(J^)-oB* (Compound 34) Using the method set forth in Example I and using benzothiohydrazide as the thiobenzoylhydrazine compound and S.7~dimethyljndoIme-2,3-dione ;JS the isatin compound, Compound 34 was prepared. Example 36 Preparation of 5-methaxy-5*-phenyKi'/J-spirofindole-S^-i 1,3.4jthiadiazol}-2(l//)-onc (Compound 35) Using the method set forth in Example 1 and using benzothiohydrazide as the thiobenzoylhydrazine compound and 5-methoxyindoline-2,3-dione as the isatin compound, Compound 35 was prepared. Example 37 Preparation of 1^4-chlorol>enxoyl)-S,-(4-niethoxyph*nyl)-3,ff-spiro(i«3-dJone as the isatin compound, Compound 36 was prepared. Example 38 Preparation of 5'-(4-metbylphcnyl>-6-propyl-3,//-spiro[indote^2-[l^,41tbi»diazo]|- 2(l//)-one (Compound 37) Using the method set forth in Example 1 and using 4-methylbenzothiohydrazide as the thiobenzoylhydrazine compound and 6-propyIindoiine-2,3-dione as the isatin compound, Compound 37 was prepared. Example 39 Preparation of l,5'-diphenyt-3,ir/-spiro{mdole-3,2,-i 13,4jthiadiazoI]-2(I//)-one (Compound 38) Using the method set forth in Example i and using btjizoibiohydnueiJe as the thiobenzoylhydrazine oampound and i -phe«yhTido]inc-2,3-d]one as the isatin coinp«M.»i-:d, Compound 38 was prepared Example 40 Preparation of 5,6-difluoro-5'-phenyl-3'//-spiro[indole-3,2'-| 1,3,4)thiadiazol|-2(l//)-one (Compound 39) Using the method set forth in Example 1 and using benzothiohydrazide as the thiobenzoylhydrazine compound and 5,6-difluoro-indoline-2,3-dione as the isatin compound, Compound 39 was prepared. Example 41 Preparation of 4,7-dichloro-5'-phenyl-3'//-spiro|indole-3,2'-[1,3,4]thiadiazol)-2(l//)-one (Compound 40) Using the method set forth in Example 1 and using benzothiohydrazide as the thiobenzoylhydrazine compound and 4,7-dichloro-indoline-2,3-dione as the isatin compound, Compound 40 was prepared. Example 42 Preparation of l-allyl-5'-phenyW/f-spiro[indole-3,2'-(1,3,4]thiadiazol)-2(l/f)-one (Compound 41) Using the method set forth in Example 1 and using benzothiohydrazide as the thiobenzoylhydrazine compound and l-allyl-indoline-2,3-dione as the isatin compound, Compound 41 was prepared. Example 43 Preparation of l-isopropyl-S'-phenyl-S'iZ-spirolindole-S^'-Il^^lthiadiaitoll-Ztli/V-oiie (Compound 42) Using the method set forth in Example 1 and using benzothiohydrazide as the thiobenzoylhydrazine compound and 1-isopropyl-indoline-2,3-dione as the isatin compound. Compound 42 was prepared. Example 44 Preparation of 5-ethyl-5'-(4-fluorophenyl)- .V//-spiro(indole-3,2'-jl,3,4]rhiadiazol)- 2(lH)-one (Compound 43) Using the method set forth in Example 1 and using 4-fluoro-benzothiohydrazide as the thiobenzoylhydrazine compound and 5-ethyl-indoiine-2,3-dione as the isatin compound, Compound 43 was prepared-Example 45 Preparation of S'^-rert-butylphenylVS-ethyl-S'/Z-spirolindole-S^'-fl^^lthiadiazolJ- 2(l/f)-one (Compound 44) Using the method set forth in Example 1 and using 4-rer/-butyl-beitzothiohydrazide as the thiobenzoylhydrazine compound and 5-ethyl-indoline-2,3-dione as the isatin compound, Compound 44 was prepared. Example 46 Preparation of l-bwtyryl-5-ethyl-5,-(4-raethylpheByl)-3'/r-spiro[in#ole-3^'-[l,3,4]thiadiazol]-2(l//)-one (Compound 45) Using the method set forth in Example 1 and using 4-rnethyl-benzothiohydrazide as the thiobenzoylhydrazine compound and l-butyryl-5-ethyl-indoline-2,3-dione as the isatin compound, Compound 45 was prepared. Example 47 Preparation of i-buryryl-S-ethyl-S'-^-methoxyphenyO-S'/Z-spirolindole-S^'-[l,3,4Jthiadiazol|-2(l//)-one (Compound 46) Using the method set forth in Example 1 and using 4-methoxy-benzothiohydrazide as the thiobenzoylhydrazine compound and l-butyryI-5-ethyl-indoline-2,3-dione as the isatin compound, Compound 46 was prepared Example 48 Preparation of 5-ethyI-5'-phcny!-3,i/-spirolindolinc-3»2,-[l,3,41thiadiazoll-2-one (Compound 47) Using the method set forth in Example 1 .md using benzotlnohydrazide as the thiobenzoylhydrazine compound and 5-ethyl-indolinc-2,3-dione as the isatm compound. Compound 47 was prepared. Example 49 Preparation of 5-ethyI-5'-(4-methylphenyl)-3'//-spiro[indoline-3,2'-[l,3,4)thiadiazol]-2- one (Compound 48) Using the method set forth in Example 1 and using 4-methylbenzothiohydrazide as the thiobenzoylhydrazine compound and 5-ethyl-indoline-2,3-dione as the isatin compound, Compound 48 was prepared. Example 50 Preparation of 5-methyl-5'-(4-methylphenyl)-3'/f-spiroIindoline-3,2'-[13»4JthiadiazolJ- 2-one (Compound 49) Using the method set forth in Example 1 and using 4-methylbenzothiohydrazide as the thiobenzoylhydrazine compound and 5-methyl-indoline-2,3-dione as the isatin compound, Compound 49 was prepared. Example 51 Preparation of 5'-(4-methylphenyl)-3'//-spiro[indolme-3,2'-( 1,3,4)thiadiazolJ-2-one (Compound 50) Using the method set forth in Example 1 and using 4-methylbenzothiohydrazide as the thiobenzoylhydrazine compound and indoline-2,3-dione as the isatin compound, Compound 50 was prepared. Example 52 Preparation of l-methyl-5'-(4-methylphenyl)-3,//-spiro(indoline-3,2,-11,3,4]thiadiazolj- 2-one (Compound 51) Using the method set forth in Example 1 and using 4-methylbenzothiohydrazide as the thiobenzoylhydrazine compound and l-methylindoline-2,3-dione as the isatin compound, Compound 51 was prepared Example S3 Preparation of l-methyI-5'-phenyl-3H-spiro|indoIine-3,2'~| l,3,4jthiadiazol)-2-one (Compound 52) Using the method set forth in Example 1 and using benzothiohydrazide as the thiobenzoylhydrazine compound and l-methylindoline-2,3-dione as the isatin compound, Compound 52 was prepared. Example 54 Preparation of 5'-phenyl-3H-spirofindoline-3,2-[l,3,4]thiadiazol]-one (Compound 53) Using the method set forth in Example 1 and using benzothiohydrazide as the thiobenzoylhydrazine compound and indoline-2,3-dione as the isatin compound, Compound 53 was prepared. Example 55 Preparation of S-bromo-S'-phenyl-S'H-spiroJindoline-S^'-l 1,3,4] thiadiazol]-2-one (Compound 54) Using the method set forth in Example 1 and using benzothiohydrazide as the thiobenzoylhydrazine compound and 5-brornoindoline-2,3-dione as the isatin compound, Compound 54 was prepared. Example 56 Preparation of 5-methyl-5'-pheiiyl-3,H-spiro(indoline-3,2,-(l,3,4|thiadiazol)-2-one (Compound 55) Using the method set forth in Example 1 and using benzothiohydrazide as the thiobenzoylhydrazine compound and 5-methyIindoline-2,3-dione as the isatin compound, Compound 55 was prepared. Example 57 Preparation of l-acetyl'5,-phenyl-3'll-spiroimdoline-3,2'-fl,3,41thiadiazol]-2-onc (Compound 56) Using the method set forth in Example 1 and using benzothiohydrazide as the thiobenzoylhydrazine compound and l-N-aeetyl-indoiine-2,3-dione as the isatin compound, Compound 56 was prepared. Example 58 Mass Spectrometry Data for Illustrative Thiadiazole Compounds Mass spectrometry data was obtained for illustrative Thiadiazole Compounds using an Agilent 1100 LC/MS instrument with an Agilent MSD detector employing the following MSD conditions (the corresponding HPLC conditions are given as (1.) in Example 59, below): Ionization Mode: API-ES; Gas Temperature: 350 °C; Drying Gas: 11.0 L/min.; Nebulizer Pressure: 55psig; Polarity: 50% positive, 50% negative; VCap: 3000V (positive), 2500V (negative); Fragmentor: 80 (positive), 120 or 140 (negative); Mass Range: 10O- l000m/z; Threshold: 150; Step size: 0.15; Gain: 1; and Peak width: 0.15 min. Mass spectrometry data for illustrative Thiadiazole Compounds listed in Table 1, below, whose listed HPLC retention times exceed 5 minutes, were obtained using alternative conditions on a Waters ZQ LC/MS instrument. The conditions were modified from those given above as follows (the corresponding alternative HPLC conditions are given as (2.) in Example 59, below): Mass spectrometry detector: Waters ZQ2000 MSD; Mass Range 100 - 700, Capillary 3.2KV, Cone Voltage 20V, Multiplier 500. Example 59 Calculation of HPLC Retention Times for Illustrative Thiadia/ole Compounds HPLC retention times were calculated for illustrative Thiadiazole Compounds vvhose retention times listed in Table 1, below, arc less than 5 minutes, using an Agilent 1 100instrument and employing the following conditions (1.): (1.) Column: Thermo Aquasil CIS, 50 x 2.1mm, 5,µm Mobile Phase A: 0.1% Formic Acid in water B: 0.1% Formic Add in ACN Flow Rate: 0.800mL/min Column Temperature: 40"C Injection Volume: 5 mL UV: monitor 215, 230, 254, 280, and 300nm Purity is reported at 254 run unless otherwise noted Solvent Gradient Table: Time (mm") %B (balance is % A) 0 5 2.5 95 4.0 95 4.1 5 5.5 5 HPLC retention times were calculated for illustrative Thiadiazole Compounds whose retention times listed in Table 1, below, exceed 5 minutes, using alternative HPLC conditions (2.) and employing a Waters ZQ LC/MS instrument. The alternative HPLC conditions (2.) were as follows: (2.) Column: Waters Xterra MS CI 8 50 mm x 2.1 mm i.d., 3.5 }xm; or Luna CI 8 30 mm x 2.1 mm i.d., 2.5 fim Flow Rate: 0.25 ml/min Run Time: 11 min Colutnn Temperature: Ambient UV; monitor 254 ran Eluent: A) 95/5 Water/Acetonitrile 0,1 %TFA B) 5/95 Water/AcetonirriieK) 1%TFA (TABLE REMOVED) Table 1, below, sets forth mass spectrometry data and HPLC retention times for Illustrative Thiadiazole Compounds, using the methods set forth in Examples 47 and 48, respectively. (TABLE REMOVED) hxaniple 61) Aggrecanusc 2 Inhibitory £ffev«s; of Illustrative I hiadia/ok- Compounds A continuous vitro fluorescence assay was employed, wherein the enzyme used in the assay was a purified recombinant human Aggrecanase-2 (Agg2-Phe(128) (MW :~ 4 1,737), which is a truncated form of full-length human aggrecanase-2 that was expressed in CHO celts and purified pnor to use. The final concentration of Agg2-Phe62« was 0.5 fig/ml. The buffer used in this assay was 50 inM HEPES, pH 7.5, 100 mM NaCl, 5 mM CaCl2, 0.1 % CHAPS, 5% glycerol. The substrate used in the assay was a synthetic peptide having the sequence ABz-TESESRGAIY-Dap(Dnp)-K.K-NH2 (>95% pure by HPLC, AnaSpec, Inc.), wherein Abz refers to ortho-aminobenzyl, a fluorescent group which is quenched by energy transfer to a 2,4-dmitrophenyl group. The final concentration of substrate in the assay was 25 \1M and was spectrophotometrically determined using the extinction coefficient at 354nm of 18,172 MT'cm"1. The Vmax and Km for this enzyme/substrate reaction were determined to be insensitive to DMSO up to at least 10% (v/V). An illustrative Thiadiazole Compound (in duplicate) was serially diluted from 2 mM to 0.01 µM in DMSO. The total reaction volume was 100 µl. The buffer and enzyme were added first followed by addition of 1 OX inhibitor from the dilution plate. Separate enzyme and buffer samples were included in order to obtain the maximal rate of substrate cleavage. The reaction was allowed to stand at 30 °C for 15 minutes, then substrate was added, the resultant solution was mixed. The resultant reaction was allowed to progress, with monitoring, for 40 minutes at 30° C in kinetic mode using v. 340 nm and kemi 420 (GeminiXS Molecular Devices). N2-{(2R)-2-[(lS)-l-Hydroxycarbamoy!-2-(thiophen-2-y]si3lfanyl)-ethylJ-4-methyl-pentanoyl}~N-memyI-L-phenylalaninamide, a hydroxamic actd with an Agg2 IC50 of 36 +/- 4 riM was run on each plate (in duplicate) as a positive control for the assay at the following concentrations: 200 nM, 20 nM and 10 nM which correspond to 100, 60 and 40 % inhibition of Agg2-Phe628 activity respectively. Data Analysis The fluorescence intensity is linear during the time of data collection. The slope of the line (Vmax/sec) represents the initial reaction rate, v. The maximal rate of cleavage of substrate was determined in the absence of inhibitor The percent inhibition of activity in the presence of inhibitor was calculated using the following equation: % inhibition = (l-v(RFIJ/sec))/Maximal Rat.- (RFU/sec))* 100 The IC50 was obtained by fitting the initial rate, v or % inhibition at each concentration of inhibitor to the following equation; y = (a-d)/(l+ C/ICso)An)+d This model describes a sigmoidal curve with an adjustable baseline, wherein: y is the % inhibition or initial rate of reaction; C is the concentration of inhibitor under test; a is die limiting response as C approaches zero. As C increases without bound y tends toward its lower limit, d; y is halfway between the lower and upper asymptotes when C— IC50; and n is the Hill coefficient. The sign of n is positive when the response increases with increasing dose and is negative when the response decreases with increasing dose (inhibition). Assay results obtained using this method are shown in Table 2 below. (TABLE REMOVED) Example 61 In vitro fluorescence assay of MMP-13 activity Materials and Methods A continuous assay is used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumann; Mca), which is quenched by energy transfer to a 2,4-dinitrophenyl group. When the peptide is cleaved by MMP, a large increase in fluorescence is observed. The source of enzyme in the assay is the recombinant human catalytic domain of MMP-13 (165 amino acids, residues 104-268, 19kDa) prepared at Wyeth-Research in Cambridge. The substrate used is the peptide Mca-PQGL-(3-[2,4~dinitrophenyl]-L-2,3-diaminoproptonyl)-AR-OH. The assay buffer consists of 50mM Hepes (pH 7.4), lOOmM NaCl, 5mM CaCl2, and 0.005% Brij-35. Each well of a 96-well plates contains a 200u.L reaction mixture consisting of assay buffer, purified MMP (final concentration of 0.5nM, prepared by diluting with the assay buffer), and varied concentrations of inhibitor (prepared by serially diluting a given inhibitor in DMSO in 96-well polypropylene plate). The plates are then incubated at 30 °C for 15 minutes. The enzymatic reactions are initiated by adding the substrate to a final concentration of 20uM, and mixing 10 times with a pipette The final DM SO concentration in the assay is about 6.0%. 'I he initial rate of the cleavage reaction can be determined at 30 "C using a fluorescence plate reader (excitation filter of 330nm and emission filter of395nm) immediately after substrate addition. Results Plots of the inhibitor concentration vs. the percent inhibition are fit to the following equation: y = (a-d)/["(x/c)b] u\, a general sigmoidal curve with Hill slope, a to d. x is the inhibitor concentration under test, y is the percent inhibition, a is the limiting response as x approaches zero. As x increases without bound, y tends toward its limit d. c is the inflection point (IC50) for the curve. That is, y is halfway between the lower and upper asymptotes when x=c. b is the slope factor or Hill coefficient. (See, Knight, et at., FEBS I^tt., 296, 263-266, (1992)). Example 62 In vitro fluorescence assay of MMP-14 activity Materials and Materials A continuous assay is used in which the substrate is a synthetic peptide containing a fluorescent group {7-methoxycoumarin; Mca), which is quenched by energy transfer to a 2,4-diniteophenyl group. When the peptide is cleaved by MMP, a large increase in fluorescence was observed. The source of enzyme in the assay is the recombinant human catalytic domain of MMP-14 (177 amino acids corresponding to Tyr89-GIy265 of mature human enzyme; 20kDa; Chemicon International, Inc. (catalog number CC1041)). The substrate used is the peptide Mca-PQGL-(3-[2,4-dinitrophenyl]-L-2,3-diaminopropionyl)- AR-OH. The assay buffer consists of 50mM Hepes (pH 7.4), l00mM NaCl, SmM CaCl2, and 0.005% Brij-35. Each well of the 96-weli plates contains a 200fiL reaction mixture consisting of assay buffer, MMP (final concentration of 25ng/ml, prepared by diluting with the assay buffer), and varied concentrations of inhibitor (prepared by serially diluting a given inhibitor in DMSO in 96-well polypropylene plate). The plates are then incubated at 30 °C for 15 minutes. The enzymatic reactions are initiated by adding the substrate to a final concentration of 20uM, and mixing 10 times with a pipette. The final DMSO concentration in the assay is about 6.0%. The initial rate of the cleavage reaction is determined at 30 °C using a fluorescence plate reader (excitation filter of 330 nm and emission filter of 395 nm) immediately after substrate addition Results Plots of the inhibitor concentration vs. the percent inhibition are fit to the following equation: y = (a-d)/[ +(x/c)b]+d, a general sigmoidal curve with Hill slope, a to d. x is the inhibitor concentration under test, y is the percent inhibition, a is the limiting response as x approaches zero. As x increases without bound, y tends toward its limit d. c is the inflection point (IC50) for the curve. That is, y is halfway between the lower and upper asymptotes when x=c. b is the slope factor or Hill coefficient (See, Knight, et al, FEBS Lett., 296, 263-266, (1992)). Example 63 In vitro fluorescence assay of MMP-2 activity Materials and Methods A continuous assay is used in which the substrate is a synthetic peptide containing a fluorescent group (7-methoxycoumarin; Mca), which is quenched by energy transfer to a 2,4-dmitrophenyl group. When the peptide is cleaved by MMP, a large increase in fluorescence is observed. The source of enzyme in the assay is the recombinant human MMP-2 (66 kDa; Oncogene Research Products (catalog number PF023 from Calbiochem)). The substrate used is the peptide Mca-PQGL-(3-[2,4-dinitrophenyl]-L-2,3- diaminopropionyl)-AR-OH. The assay buffer consists of 50mM Hepes (pH 7.4), lOOmM NaCl, 5mM CaCl2, and 0.005% Brij-35. Each well of a 96-well plate contains a 200uL reaction mixture consisting of assay buffer, MMP (final concentration of 25ng/ml, prepared by diluting with the assay buffer), and varied concentrations of inhibitor (prepared by serially diluting a given inhibitor in DMSO in 96-well polypropylene plate). The plates are then incubated at 30 °C for 15 minutes. The enzymatic reactions are initiated by adding the substrate to a final concentration of 20uM, and mixing 10 times with a pipette. The final DMSO concentration in the assay is about 6.0% The initial rate of the cleavage reaction is determined at 30 °C using a fluorescence plate reader (excitation filter of 330nm and emission filter of 395nm) immediately after substrate addition. Results Plots of the inhibitor concentration vs. the percent inhibition are fit to the following equation: y = (a-d)/[ +(x/c)b]+d, a general sigmoidal curve with Hill slope, a to d x is the inhibitor concentration under test, y is the percent inhibition, a is the limiting response as x approaches zero. As x increases without bound, y tends toward its limit d. c is the inflection point (IC50) for the curve. That is, y is halfway between the lower and upper asymptotes when x=c. b is the slope factor or Hill coefficient (See, Knight, C.G., Willenbrock, F., and Murphy, G. FEBSLett. (I9y2) 296, 263-266). While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention. What is claimed is: 1 - A compound having the Formula: (Formula Removed) or a pharmaceutieally acceptable salt or hydrate thereof, wherein X is -(CH2)m-C(O)O-, ~(CH2)m-C(O)NH- or ~(CH2)m-SO2-, m is Oor 1; eaehY is-C(R3)s R1 is -aryl or -5 or 6-membered aromatic or non-aromatic heterocycle, wherein the -aryl or -5 or 6-membered aromatic or non-aromatic heterocycle group is unsubstituted or substituted with one or more R4 groups; R2 is -H, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 aikyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6, alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein the -C1-C6 alkyl, -C2-C6, alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstituted or substituted with one or more of the following groups: -halo, -O-Ct-Q alkyl, -O-C2-C6 alkenyl, -O-C2-C6 alkynyl, -O-aryl, -O-(C1- C6 atkyl)-aryl, 0(5 or 6-membered aromatic or non-aromatic heterocycle), -O-(C1-C6 a!kyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2~C6, alkynyl, -CF3, -OCF3, -NO2, -NH7, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alky!), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, -NHSO2(C1-C6 aikyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2, each R1 is independently -H, -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -{C1-C6 alky!)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterncyclej-aryl, -(5 or 6- memrered aromatic or non-aiomatic hetevocyc!e)-CH2 .aryl, (5 os o-membered aromatic 01 non-aromatic heterocyclehC1-C6. alkyl, -NH2. -NH(C1-C6, alkyl), -N(C|-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkylK -NHSO2(C|-C6 alkyl), -C(O)O-(Ci-C<; alkyl), -C(O)NH(C, C6 alkyl), or C(O)N{C,~ C6 alkyl)2; and each R4 is independently halo, -OR2, -CN, -C1-C6 alkyl, -C2~C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3) -NO2, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic hetcrocycle), -(5 or 6-membeTed aromatic or non-aromatic he?erocycle)-aryl, -(5 or 6-membered aromatic or non-aromatic heterocyele)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C 1-C6 alkyl, -NH2, -NH(C,-C5 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2-NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1,~ C6 alkyl)2. 2. A compound having the Formula: (Formula Removed) or a pharmaceutically acceptable salt or hydrate thereof, wherein X1 is -CH2-, -(CH2)m-C(O)-, -(CH2)m-C(O)NR2-, -(CH2)m-C(O)O-, -(CHj)m-C(O)NH- or -(CH2)m-SO2-; m is 0 or 1; n is 0 or 1; each Y is independently -C(R3)- or -N-, wherein at least one occurrence of Y1 is -N-, R is -aryl or -5 or 6-membered aromatic or non-aromatic hetcrocycle, wherein the -aryl or -5 or 6-membered aromatic or non-aromatic heterocycle group is unsubstttuted or substituted with one or more R groups, R2 is -H, -C1-C6 alkyl, -C2-C6. alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein the -C1-C6 alkyl, -C2-C6, alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatvc heterocycle) group is unsubstituted or substituted with one or more of the following groups: -halo, -O-C1-C6 alkyl, -O-C1-C6 alkenyl, -O-C2-C6 alkynyl, -O-aryl, -O-(C|-Cfi alkyl)-aryl, -G-(5 or 6-membered aromatic or non-aromatic heterocycle), -O-(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -CN, -C|-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -NH2( -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2) -NHSO2(C1-C6, alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C, C6 alkyl), or -C(O)N(C1-C6 alkyl)2; each R3 is independently -H, -halo, -OR2, -CN, -C1-C6 alkyl, ~C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NQz, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycliC1-C6 alkyl, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C|-C6 alkyl)2; and each R4 is independently -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6; alkynyl, -CF3, -OCF3, -NO2, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C1-C6 alkyl, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkylfc, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C.-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C, Cb alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C,-C6 alkyl)2- 3. A compound having the Formula: (Formula Removed) or a pharmaceutically acceptable salt or hydrate thereof, wherein X! is -CH2-, -(CH2)m-C(O)-, -(CH2)m-C(O)NR2-, -(CH2)m-C(O)O-, -(CH2)m-C(O)NH- or-(CH2)m-SO2s m is 0 or 1; n is 0 or 1; each Y is independently -C(R3)- or -N-; R5 is -5 or 6-membered aromatic or non-aromatic heterocycle, which is unsubstituted or substituted with one or more R4 groups; R2 is -H, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, (C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyi)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein the -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic, or non-aromatic heterocycle or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstituted or substituted with one or more of the following groups: -halo, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, -O-C2-C6 alkynyl, -O-aryl, -O-(C1-C6 aikyl)-aryl, -O-(5 or 6-membered aromatic or non-aromatic heterocycle), -O-(C1-C6 alkyI)-(5 or 6-membered aromatic or non-aromatic heterocycle), -CN, -C1-C6 alkyl, -C2-C6 alkenyl, C2-C6 alkynyl, -CF3, -OCF3, -N02, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkylh, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 afkyl).; each R3 is independently -H, -halo, -OR2, -CN, -C1-C6 alkyl, -C1-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle) CH7-aryl, -(5 or 6-membered aromatic or nor. aromatic heterocycie) C1- C6 alky], -NH2, -NH(C1- C6 alkyl), -N(C1- C6 alkyl)2, -NHC(O) (C1-C6alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C:6 alkyl), -SO2C1-C6. alkyl)2, -NHSO2(C1-C6 alkyt), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6, alkylj; and each R4 is independently -halo, -OR2. -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C1-C6, alkynyl, -CF3, -OCF3, -NO2, -(C1-C6. alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycie), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryi, -(5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C1-C6 alky!, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl}2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 aJkyl), -SO2NH2, -SO2NH(Cl-C6 alkyl), -SO2N(C1-C6, alkyl)2, -NHSO2(C1-C6 aJkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C,C6 alkyl), or -C(O)N(Ct-C6 alkyl)2. 4. A compound having the Formula: (Formula Removed) or a pharmaceutically acceptable salt or hydrate thereof, wherein X2 is -CH2-, -(CH2)m-C(O)O-, -(CH2),r-C(O)NH-, -(CH2)m-C(O)NR2-, or -(CH2)m-SO2-; each Y is independently -C(R3)- or -N-, m is 0 or 1; n is 0 or 1; R2 is -H, -C1-C6 alkyl, -C1-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-rnetnbered aromatic or non-aromatic heterocycie, or -(C1-C6 alkyi)-(5 or 6-membered aromatic or non-aromatic heterocycie), wherein the -C1-C6 alkyt, -C2-C6 alkenyl, ~C2-C6 alkynyl, -aryl, -(C1-C6, alkyt)-ary), -5 or 6-memhered aromatic or non-aromatic heterocycie, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycie) group is unsubstituted or substituted with one or more of'the following groups: -halo, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, -OC2-C6 alkynyl, -O-aryl, -O-(C1-C6 alkyl)-aryl, -O-(5 or 6-membered aromatic or non-aromatic heterocycle), -O-(C1-C6 alky])-(5 or 6-membered aromatic or non-aromatic heterocyele), -CN, -C1-C6 alkyl, -C1-C6 alkenyl, -C2-C6 alkynyl, -CF3 -OCF3 -NO2, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1- C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6, alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2; and each R3 is independently -H, -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C1-C6 alkyl, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2. wherein the —OCH3 depicted in Formula (IV) occupies the para position or an ortho or meta position on the phenyl ring to which it is attached. 5. A compound having the Formula: (Formula Removed) or a pharmaceutically acceptable salt or hydrate thereof, wherein X3 is -CH2-, -(CH2)m-C(O)O-, -(CH2)ra-C(O)NH-, or -(CH2),n-SO2-; each Y is independently -C(R ) or -N-; m is 0 or 1; n is 0 or I; each R6 is independently - H1 -C1-C6, alkyl, or -halo; R7 is -H, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryh -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein a -C1-C6; alkyl, -C1-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -{C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstituted or substituted with one or more of the following groups: -halo, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, -O-C2-C6; alkynyl, -O-aryl, -O-(C1-C6 alkyl)-aryl. -O-(5 or 6-membered aromatic or non-aromatic heterocycle), -O-(C1-C6 alkyl)-(5 or 6-rnembered aromatic or non-aromatic heterocycle), -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6, alkynyl, -CF3, ~OCF3, -NO2, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2l -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SOaNH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, -NHSO2C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), such that when n is 0, R7 is not -H; and each R8 is independently -CN, -Ct-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2. -(C1-C4 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -(5 or 6-membered aromatic or ron-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C1-C6 alkyl, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC{O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 aikyl)2, -NHSO2(C1-C6 alkyi), -C(O)O(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N{C1-C6 alkyl)2. 6. A compound having the Formula: (Formula Removed) or a pharmaceuticaUy acceptable salt or hydrate thereof, wherein X4 is -CH2-, -C(O)-, -(CH2)m-C(O)O-. -(CH2)m-C(O)NH, or (CH2)m--SO2, each Y is independently -C(R3)- or -N-; m 1 s 0 or 1; n is 0 or 1; each R9 is independently -H, -C1-C6 alkyl, -O-C1-C6, alkyl, or -halo; R2 is -H, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein the -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstituted or substituted with one or more of the following groups: -halo, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, -O-C2-C6 alkynyl, -O-aryl, -O-(C1-C6 alkyl)-aryl, -O (5 or 6-membered aromatic or non-aromatic heterocycle), -O-(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2; and each R3 is independently -H, -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CF3, -OCF3, -NO2, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non-aromatic heterocycle)-aryl, -{5 or 6-membered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membered aromatic or non-aromatic heterocycle)-C1-C6 alkyl, -NH2, -NH(C1-C6 alkyl), N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C1-C6 alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C,-C6 alkyl)2, such that: every R and every R3 are not simultaneously —H when n is 0 and R2 is -H, methyl, ethyl, butyl, pentyl, or an unsubstituted or mono- or di-substituted —(C1-C6 alkyl)-aryl; R9 and R2 are not simultaneously -H when n is 0, exactly one R3 group is bromo, isopropyl, ethyl, or methyl and the other R3 groups are -H; R2 is not naphthyl, methyl, butyl, or pentyl when every R9 and RJ group is -H and n is 0; R2 is not -H or methyl when n is 0, exactly one R group is methyl while the other R9 groups are -H, and every R3 group is -H or exactly one R3 group is methyl or ethyl while the other R groups are H; R2 is not naphthyl substituted with exactly one halo or one -NO2 group, or phenyl substituted with exactly one -halo or one -N02 group, when (X)„ is -CH2- and every R9 and R3 group is -H or exactly one R9 group is methyl and the other R9 and R3 groups are -H; R is not -H, methyl, or -(C1-C6 alkyl)-(5 or 6-rnembered non-aromatic heterocycle) when exactly one R9 group is methyl, n is 0, and every R3 group is -H; A is not —C(O)- and R is not propyl or methyl when every R is -H, n is 1, and every R9 is-H or exactly one R9 is—O-(C1-C6 alkyl) and the other R9 groups are-H; exactly one R group is not methyl, ethyl, or isopropyl when the other three R3 groups are —H, and each R group.is -H or the R group at the para position is methyl and the other R9 groups are -H, and R2 is -H; and the R3 groups do not comprise exactly one methyl and exactly one -halo or the R3 groups do not comprise exactly two methyl groups at the 6 and 7 positions of the indoline ring when n is 0 and R2 and every R9 are -H. 7. The compound, of claim 4, wherein each occurrence of Y is —C(R3)-, 8. The compound of claim 4, wherein each occurrence of Y is —CH-. 9. The compound of claim 4, wherein the -OCH3 depicted in Formula (IV) occupies the para position on the phenyl ting to which it is attached. 1 0. The compound of claim 4, wherein the -OCH3 depicted in Formula (IV) occupies a rneta position on the phenyl ring to which it vs attached. 1 1. The compound of claim 4, wherein n is 0 and R2 is-H, -C1-C6 alkyl, -C2-C6 alkynyl or -(C1-C6, aikyl)-aryl. 12. The compound of claim 8, wherein at least one occurrence of R3 is -halo, -C1-C6 alkyl, or-NO2. 13. The compound of claim 5 wherein each occurrence of Y is -~C(R8)- 14. The compound of claim 6 wherein each occurrence of Y is -C(R3)-. 1 5 The compound of' claim 14, wherein cach.occimence. of Y i.s CH-. 16. The compound of claim 14, wherein each occurrence ol'R' is-H. 3 7. The compound of claim 14, wherein n is 0 and R2 is aryl, -C1-C6 alkyi or -(C1-C6 aikyl)-aryl. 1 8. The compound of claim 14, wherein at least one occurrence of R is —C1-C6 alkyl, -CF3, -5 or 6-membered aromatic or non-aromatic heterocycle or -OCF3. 19. A compound being: 5,-(4-methoxyphenyl)-5,7-dimethyi-3'H-spiro[indole-3,2'-[l,3,4]thiadiazol]-2(lH)-one; 5H4-methoxyhimyl)-l-memyl-3H-spiro[indole-3,2413,43thiadia2oI]-2(lH)-one; 5'-(4-methoxyphenyl)-3H-spirof indole-3,2'-[ 1,3,4)thiadiazol]-2( 1 H)-(me; 5-taomo-5-(4-mrthoxyphenyl)-3H-spiro[indole-3,2'-[l3,43thiadiazoll-2(lH)-one; 5-(4-metboxyphenyl)-5-methyl-3 H-spiro[indole-3,2'-[ 1,3,4]thiadiazol]-2(lH)-one; 5-meth©xy-5-[4-methoxyphenyl)-3 H-spiro[indole-3,2'-[ 1,3,4]thiadiazol3-2(1H)-one; 5'-(4-methoxyphenyl)-1 -prop-2-yn-l -yl-3'H-spiro[indole-3,2'-[ 1,3,4]thiadiazol3-2(lH)-one; 5,-(4-methoxyphralyl)-l-[3-(trifluoromethyl)phenyi]-3'H-spiro[indole-3>2,-[ 1,3,4]thiadiazol]-2(l H)-one; ethyl [5'-{4-methoxyphenyl)-2-oxo-3'H-spiro[rndole-3,2'-[ 1,3,4]thiadiazol]-1(2H)~ yl]acetate; l-benzyl-5'-{4-methoxyphenyl)-3,H-spiro[indole-312,-H,3,4]thiadJazol]-2(lH)-one; 1 -[2-(dimethylamino)ethyl]-5'-(4-methoxyphenyl)-3'H-spjro[ indole-3,2'-[ t,3,4]thiadia2ol]-2(lH)-one; 6-chloro-5'-{4-methoxyphenyl)-3H-spiro[mdole-3,2'-[lI3,4Jthiadia2ol]-2(lH)-one; 5-ch!oro-5'-(4-methoxyphenyl)-3'H-spiro[indole-3)2'-[l ,3,4]thiadiazot]-2(lH)-one; 4-(4-benzylpipera2in-t-y])-5,-(4-rnethoxyphenyI)-3'H-spiro[indole-3,2'-[ 1,3,4]thiadiazot]-2(lH)-one; 5'-(4-methoxyphenyl)-6-propyl-3H-sptro[indole-3)2'-{l ,3,43thiadirixol]-2(lH)-one, 5,-(4-methoxyphenyl)-5-nitro-3,H-spirotindole-3,2'-{I,3.4]thia.ol]-2{lH)-one, 6-chloro-5'-(4-methoxypheriyl 7 mcthyl- 3H:,piro[ indole-3,2'-{ i ,3,4jthiadiazol]-2( 1 fI)-one; 5'~(4-methoxyphenyl)-7-methyl-3H-spiro[ indole-3,2'-[ 1,3,4]thiadiazol]-2(lH)-one, 5'-(4-methoxyphenyl)-6-rnethyl-3,H-spiro[indoit:-3,2'-[l,3>4]thiadiazolj-2(lH)-one; ?-methoxy-5'-(4-methoxyphenyJ)-6-methyl-3H-spiro[indole-3,2,-[l,3,4]thiadiazol]' 2(lH)-one; I-ethy!-5-fluoro-5'-(4-methoxyphenyl)-6-(4-methy|piperaz:in-I-yl)-3,H-spiro|indole-3,2'-[1,3)4]thiadiazol]-2(lH)-one; 1 -benzyl -5'-(4-methoxyphenyl)-5-rnethyl-3'H-sp:ro[indo]e-3,2'-[l ,3,4]thiadiazol]-2(lH)-one; 5-(4-methoxyphenyl)-5-methyl-l-{2-methylphenyO-3,H-spiro[indole-3,2*-[ 1,3,4]thiadiazol]-2(lH)-one; 5'-(4-metboxyphenyt)-5 -methyl -1 -(4-methylphenyl)-3 H-spiro[ indo!e-3,2'-[ 1,3,4]thiadiazol]-2(l.H)one; 1 -(4-chlo^opbcnyl)-5,-(4-methoxyphenyl)-5-methyl-3H-spiro[indole-3,2•-[ 1,3,4]thia«lia2ol]-2( lH)-one; l-(3,4-ichloro{menyt)-5'-(4-methoxyphenyl)-5-methyl-3,H-spiro[indole-3,2'-[ 1 ,3,4]thiadiazoi;)-2( lH)-one; - 5'-(4-methoxyphenyl)-5-methyl-1-(3-nitrophenyI)-3H~spiro[indole-3,2'-[ 1,3,4]thiadiazol]-2( lH)-one; l-benzyI-5'-(4-niethoxyphenyl}-6-propyl-3'/V-spiro[indole-3,2'-[l,3,43th!adiazoi]-2(lH)-one; 5-ethyl-5'-(4-methoxyphenyl)-3,H-spiro[mdole-3,2,-[l,3,4]lhiadiazol]-2(lH)-one; 5-ethyl-5,-(3-methoxyphenyl)-3H-spiro[indo[e-3,2'-ll,3,4]thiadiazol]-2(lH)-orie! 5'-phenyl-5-(triiflvoromethoxy)-3'H-spiro[indole-3)2'-[l ,3,4]thiadiazol]-2(lH)-one; 5-methyl-l-(2-methylphenyl)-5,-(4-methylphenyl)-3'H-spiro[indole-3)2'-[ 1,3,4]thiadiazol]-2( lH)-one; i-benzyl-5-methyl-5,-(4-methylphenyl)-3'H-spiro[indole-3,2'~[l,3,4]LhiadiazolJ-2(lH)-one, 5,7-diTnethyl-5,-pheny]-3'H-spiro[indole-3!2-[ 1 ,3,4]thiadiazol]-2( 1 H)-one; 5-methoxy-5'-phenyl-3'H-spiro[indoie-3,2'-[l,3,4]thiadiazol]-2( 1H)one; l-(4-chiorobcnzoy!)-5'-(4-methoxyphenyl)-3 H-spiro|indole-3,2l-[ ] ,3,4]thiadiazol]-2(iH}-one; 5'-(4-methylphenyl)-6-propyi-3H .spirofindole--3,2" f l,3,4]thiadiazol]-2(1H)one J,5'-djpheny]-3H-spiro[incio]e-..'1,2'-[ !,3,4]thiadiazol]-2(1,H-one, 5,6-difluoro-5'-phenyl-3H-spiro[indole-3,2-[ ,3,4thiadiazol]-2(1H}-one; 4,7-dichloro-5'-phenyl-3H-spiro[indo]e-3,2'-[l ,3,4[thiadiazol]-2(lH)-one; l-ai]y\-5'~pheny]-3'H-sp\To[mdo\e-3,2'-[l3,4)thiadiazol]-2(lH)-one: i-isopropyl-5,-phenyl-3H-spiro[indoIe-3,2'-[l,3,4]thjadiazol]-2(lH)-one; 5-ethyl-5,-(4-fluorophenyl)-3'H-spiTo[indole-3,2'-[ 1,3,4]thiadiazol]-2(l H)-onc; 5'-{4-tert-buty]phenyl)-5-ethyl-3'H-spiro[iridole-3,2-ri,3,4]lhiadia2oS]-2(l/Y)-one; J-butyryl-5-ethyJ-5'-(4-methylphenyJ)-3'H-spiro[fXjdole-3,2,-[1,3,4]thiadiazo]]-2{]H)-one; or l-butyryl-S-ethyl-5'-(4-methoxyphenyl)-3H-spiro[3ndole-3,2'-[ 1,3,4]thiadiazolj-2(\H)-one; or a pharmaceutically acceptable salt or hydrate thereof. 20. A pharmaceutical composition comprising the compound of any one of claims 1 to 19 or a pharmaceutically acceptable salt or hydrate thereof, and a physiologically acceptable vehicle. 21. A method of treating or preventing a disorder in a mammal in need thereof, which comprises administering an effective dose of the compound of any one of claims I to 20 ot a pharmaceutically acceptable salt or hydrate thereof, wherein the disorder is an arthritic disorder, osteoarthritis, cancer, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia, or a periodontal disease. 22. A method of treating or preventing a disorder in a mammal in need thereof, which comprises administering an effective dose of a compound having the Formula: (Formula Removed) or a pharmaceuticaily acceptable salt or hydrate thereof, wherein X4 is -CH2-, -C(O)-, -(CH2)m-C(O)O-, -(CH2)m-C(O)NH, -(CH2)m-C(O)NR2, or -(CH2)m-SO2-; each Y is independently -C(R3)- or -N-; m is 0 or 1; n is 0 or 1; each R9 is independently —H, -C1-C6 alkyl, -O -C1-C6 alkyl, or halo; R2 is -H, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C6 alkyl)-{5 or 6-membered aromatic or non-aromatic heterocycle), wherein the -C1-C6 alkyl, -C2-C6 alkenyl, -C3-C6 alkynyl, -aryl, -(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle, or -(C1-C4 aIkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstituted or substituted with one or more of the following groups: -halo, -O-C1-C6 alkyl, -O-C2-C6 alkenyl, -OC2-C6 alkynyl, -O-aryl, -O-(C1-C6 alkyl)-aryl, -O(5 or 6-rnembered aromatic or non-aromatic heterocycle), -O-(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, CF3, -OCF3, -NOj, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -NHC(O)-(C1-C6 alkyl), -NHC(O)NH(C1-C6 alkyl), -SO2NH2, -SO2NH(C1-C6 alkyl), -SO2N(C,-C5 alkyl)2, -NHSO2(C1-C6 alkyl), -C(O)O-(C1-C6 alkyl), -C(O)NH(C1-C6 alkyl), or -C(O)N(C1-C6 alkyl)2; and each R3 is independently -H, -halo, -OR2, -CN, -C1-C6 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -CFj, -OCF3, -N02, -(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), -(5 or 6-membered aromatic or non aromatic heterocycle)-aryl, -(5 or 6-mernbered aromatic or non-aromatic heterocycle)-CH2-aryl, -(5 or 6-membcred aromatic or non-aromatic heterocycle) C1-C6 alkyl, -NH2, -NH(C1- C6 alkyl), -N(C1-C6 atkyl)2, -NHC(O)-(C1-C6 alkyi), -NHC(O)NH(C1-C6 alkyl), -SO2NH, -SO2NH(C1-C6 alkyl), -SO2NC1-C6, alkyl)2. -NHSO2(C1-C6, alky]}, -C(O)O (C1-C6 alkyl), ■('|())NII|(.C1-C6 alkyl), or ( (O)N(C1- C6alkyl)2, wherein the disorder is an arthritic disorder, osteoarthritis, cancer, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface disease, hepatitis, an aortic aneurysm, tendonitis, a central nervous system disorder, abnormal wound healing, angiogenesis, restenosis, cirrhosis, multiple sclerosis, glomerulonephritis, graft versus host disease, diabetes, an inflammatory bowel disease, shock, invertebral disc degeneration, stroke, osteopenia, or a periodontal disease. 2 3. The method of claim 22, wherein the compound is: S-ethyl-5-phenyl-3H-spiro[indoie-3,2-[l,2,3] thiadtazol]-2(lH)-one; 5-ethyl-5'-(4-methyiphenyl)-3'H-spiro[indoIe-3,2'-[l,3,4]thiadia2ol]-2(lH)-one; 5-me»hyl-5'-(4-methylphenyl)-3,H-spiro[indo1e-3J2,-[ 1,3,4]thiadiazoll-2(] H)-one; 5,-(4-methylphenyl)-3'H-spiro[indole-3,2,-[l ,3,4]thiadiazol]-2(lH)-one; 1 -methyl-5H-naethy-C 1,3,4]thiadiazol]~2( I H)-one; l-meftyl-5'-phenyl-3,H-spiro[indoHne-3,2,-[ 1,3,4]thiadiazol]-2-one; 5,-phenyl-3*H-spiro|iBdoline-3,2-[ 1,3,4]thiadiazol]-2-one; 5-bromo-5'-pliaayl-3'H-spiro[indoline-3,2,-[ 1,3,4]thiadiazol]-2-one; 5-methyI-5'-phenyl-3'H-spiro[mdohne-3,2'-[ 1,3,4]thiadiazol ] -2-one; or I -acetyl-5'-phenyl-3'H-spiro[indohne-3,2'-[ 1,3,4]thiadiazol]-2-one; or a phsrniaceutically acceptable salt or hydrate thereof. 24 The method of any one of claims 21-23, wherein the disorder is osteoarthritis 25. The Invention substantially such as herein before described.